Spherusol market forecast points to growth as valley fever cases rise

The Business Research Company says the global Spherusol market is set for continued expansion through 2035, driven by rising coccidioidomycosis cases, stronger public health screening and broader use of diagnostic skin tests. North America led the market in 2025 and is expected to remain the fastest-growing region.

Why it matters: - Rising valley fever cases and wider screening efforts are pushing attention toward Spherusol, a skin test used to detect prior exposure to coccidioides fungi. - The market’s growth could affect infectious disease surveillance, endemic-area testing and immune-response diagnostics.

What happened: - The Business Research Company published its Spherusol Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on November 11, 2026. - The report says the Spherusol market is gaining traction as awareness of coccidioidomycosis and diagnostic methods improves. - The report covers market size, trends, forecasts and regional performance across North America, Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company also offered a free sample of the report and the full market report.

The details: - Spherusol is a diagnostic skin test that measures delayed-type hypersensitivity after exposure to coccidioides fungi. - The test is read 48 hours after injection and is used to identify prior exposure, not active infection. - The fungi are linked to valley fever, also called coccidioidomycosis, and are commonly found in dry, sandy environments. - The report says market growth has been supported by better knowledge of coccidioidomycosis epidemiology, more reliance on serological testing, expanded public health screening and wider availability of standardized diagnostic reagents. - The report expects more growth from higher investment in infectious disease surveillance, demand for early detection tools, expanded testing in endemic regions, deeper research into immune-response diagnostics and broader use of preventive healthcare diagnostics. - The report highlights growing use of advanced diagnostic skin tests, delayed-type hypersensitivity diagnostics and fungal infection monitoring programs. - The report says North America held the largest market share in 2025 and is expected to remain the fastest-growing region during the forecast period. - The report cites August 2025 data from the California Department of Public Health showing more than 5,500 provisional valley fever cases in the first half of 2025, after nearly 12,500 cases in 2024. - The report cites June 2024 data from the Outdoor Industry Association showing organized outdoor recreation rose 4.1% in 2023 to 175.8 million participants, or 57.3% of the U.S. population. - The report cites a January 2024 Population Reference Bureau projection that the U.S. population age 65 and older will rise from 58 million in 2022 to 82 million by 2050, while the share of the total population increases from 17% to 23%.

Between the lines: - The report ties market demand to broader public health and demographic trends, not just product-specific adoption. - Rising cases in endemic areas and more outdoor exposure may increase the need for diagnostic tools that can flag prior fungal exposure. - The aging population could widen the addressable patient base for immune-related diagnostics, though the report does not quantify Spherusol-specific usage by age group. - The report also positions Spherusol within a larger shift toward earlier detection and more structured infectious disease surveillance.

What's next: - The report expects continued market expansion through 2035 as screening, surveillance and endemic-region testing broaden. - The Business Research Company said its 2026 reports include added strategic intelligence such as market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards and market-hotspot infographics. - The company listed media and sales contacts for further information, including Saumya Sahay and marketing@tbrc.info.

The bottom line: - Spherusol is moving from a niche diagnostic into a market buoyed by rising valley fever incidence, stronger screening programs and broader interest in immune-based testing.